SLRN - ACELYRIN, Inc.

QQQ $ 473.14 $ -2.10 (-0.44 %)

DIA $ 417.33 $ 2.44 (0.59 %)

SPY $ 562.48 $ 0.83 (0.15 %)

TLT $ 101.29 $ 0.92 (0.92 %)

GLD $ 238.61 $ -0.02 (-0.01 %)

Previous Close

$ 4.31

Open

$ 4.86

Bid

$ 4.30 x 200

Ask

-- x --

Day's Range

$ 4.20 - $ 4.86

52 Week Range

$ 3.36 - $ 11.23

Volume

848,701

Average Volume

Market Cap

430.17M

Beta (5Y Monthly)

$ 0.82

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-13-2024	06-30-2024	10-Q
2	05-14-2024	03-31-2024	10-Q
3	03-28-2024	12-31-2023	10-K
4	11-09-2023	09-30-2023	10-Q
5	08-14-2023	06-30-2023	10-Q
6	06-15-2023	03-31-2023	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Acelyrin Announced That Data From Its Phas...
09/10/2024 11:03:11

fabrinet-posts-strong-earnings-joins-amer-sports-hawaiian-holdings-and-other-big-stocks-moving-higher-on-tuesday

Fabrinet Posts Strong Earnings, Joins Amer...
08/20/2024 14:07:32

Morgan Stanley Maintains Equal-Weight on A...
08/19/2024 16:59:05

Morgan Stanley analyst Vikram Purohit maintains Acelyrin (NASDAQ:SLRN) with a Equal-Weight and lowers the price target from ...

HC Wainwright & Co. Downgrades Acelyrin to...
08/15/2024 17:21:17

HC Wainwright & Co. analyst Emily Bodnar downgrades Acelyrin (NASDAQ:SLRN) from Buy to Neutral and lowers the price targ...

acelyrin-cuts-workforce-deprioritizes-former-lead-drug-izokibep

Acelyrin Cuts Workforce, Deprioritizes For...
08/14/2024 16:29:04

Acelyrin reports promising Phase 3 results for izokibep in hidradenitis suppurativa, announces a strategic focus on lonigutamab.

Piper Sandler Maintains Overweight on Acel...
08/14/2024 16:04:37

Piper Sandler analyst Yasmeen Rahimi maintains Acelyrin (NASDAQ:SLRN) with a Overweight and lowers the price target from $68...

ouster-reports-weak-sales-joins-brinker-international-and-other-big-stocks-moving-lower-in-wednesday-pre-market-session

Ouster Reports Weak Sales, Joins Brinker I...
08/14/2024 12:27:29

Acelyrin Q2 2024 GAAP EPS $(0.86) Misses $...
08/13/2024 20:02:01

Acelyrin (NASDAQ:SLRN) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.69) by...

ACELYRIN Announces Phase 3 Izokibep Trial ...
08/13/2024 20:01:01

why-arhaus-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-mondays-mid-day-session

Why Arhaus Shares Are Trading Lower By Aro...
07/08/2024 17:16:55

Wells Fargo Upgrades Acelyrin to Overweigh...
07/08/2024 13:40:23

Wells Fargo analyst Derek Archila upgrades Acelyrin (NASDAQ:SLRN) from Equal-Weight to Overweight and maintains the price ta...

HC Wainwright & Co. Maintains Buy on Acely...
05/22/2024 10:11:47

HC Wainwright & Co. analyst Emily Bodnar maintains Acelyrin (NASDAQ:SLRN) with a Buy and raises the price target from $1...

HC Wainwright & Co. Reiterates Buy on Acel...
05/15/2024 15:44:40

HC Wainwright & Co. analyst Emily Bodnar reiterates Acelyrin (NASDAQ:SLRN) with a Buy and maintains $16 price target.

HC Wainwright & Co. Maintains Buy on Acely...
05/09/2024 17:55:25

HC Wainwright & Co. analyst Emily Bodnar maintains Acelyrin (NASDAQ:SLRN) with a Buy and lowers the price target from $2...

ACELYRIN Founder Shao-Lee Lin Steps Down A...
05/09/2024 12:32:09

HC Wainwright & Co. Reiterates Buy on Acel...
04/01/2024 10:47:36

HC Wainwright & Co. analyst Emily Bodnar reiterates Acelyrin (NASDAQ:SLRN) with a Buy and maintains $28 price target.

Acelyrin Q4 EPS $(0.75) Beats $(0.99) Esti...
03/29/2024 03:38:04

Acelyrin (NASDAQ:SLRN) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.99) by 2...

Wells Fargo Maintains Equal-Weight on Acel...
03/21/2024 12:09:30

Wells Fargo analyst Derek Archila maintains Acelyrin (NASDAQ:SLRN) with a Equal-Weight and raises the price target from $11 ...

investors-cheer-acelyrins-stock-its-second-lead-candidate-shows-clinical-benefit-in-thyroid-eye-disease-patients

Investors Cheer Acelyrin's Stock, Its Seco...
03/20/2024 16:34:06

Acelyrin releases Phase 1/2 trial results of lonigutamab. Rapid improvements in eye bulge and double vision. Well-tolerated wit...

HC Wainwright & Co. Reiterates Buy on Acel...
03/20/2024 16:11:23

HC Wainwright & Co. analyst Emily Bodnar reiterates Acelyrin (NASDAQ:SLRN) with a Buy and maintains $30 price target.